NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
GlobeNewswire
· New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study..